We are live on ! Find out more
IBT

International Biotechnology Trust Portfolio holdings

AUM $297M
1-Year Est. Return 17.25%
This Fund
S&P 500
This Quarter Est. Return
+9.76%
1 Year Est. Return
+17.25%
3 Year Est. Return
+11.14%
5 Year Est. Return
+79.35%
10 Year Est. Return
–
AUM
$210M
AUM Growth
-$50M
Cap. Flow
-$601K
Cap. Flow %
-0.29%
Top 10 Hldgs %
49.98%
Holding
57
New
3
Increased
11
Reduced
5
Closed
6

Top Buys

Rank Stock Value
1
AERI
Aerie Pharmaceuticals
AERI
+$7.1M
2
CELG
Celgene Corp
CELG
+$5.66M
3
ZGNX
Zogenix, Inc.
ZGNX
+$5.6M
4
INCY icon
Incyte
INCY
+$5.08M
5
EXEL icon
Exelixis
EXEL
+$5.07M

Top Sells

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$14.5M
2
BIIB icon
Biogen
BIIB
+$10.5M
3
SAGE
Sage Therapeutics
SAGE
+$4.17M
4
ASXC
Asensus Surgical, Inc.
ASXC
+$3.82M
5
IONS icon
Ionis Pharmaceuticals
IONS
+$3.52M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RSLS
51
DELISTED
ReShape Lifesciences Inc. Common Stock
RSLS
$2K ﹤0.01%
375
– –
BIIB icon
52
Biogen
BIIB
$32.7B
– –
-36,208
Closed -$10.5M
RIGL icon
53
Rigel Pharmaceuticals
RIGL
$875M
– –
-37,000
Closed -$1.04M
VKTX icon
54
Viking Therapeutics
VKTX
$3.95B
– –
-70,000
Closed -$664K
VSTM icon
55
Verastem
VSTM
$668M
– –
-41,667
Closed -$3.44M
ASXC
56
DELISTED
Asensus Surgical, Inc.
ASXC
– –
-68,391
Closed -$3.82M
PTLA
57
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
– –
-24,000
Closed -$906K
1 2
3

Similar funds

DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
DT
Daniels + Tansey Wilmington, Delaware $289M AUM 18.06% 1-Year Est. Return
3LCM
3D/L Capital Management Hartford, Connecticut $308M AUM 13.67% 1-Year Est. Return
TFA
Triad Financial Advisors Greensboro, North Carolina $284M AUM 14.95% 1-Year Est. Return
SFG
Steward Financial Group Colleyville, Texas $315M AUM 13.78% 1-Year Est. Return
AEPLI
AH Equity Partners LSV I Menlo Park, California $315M AUM 9.31% 1-Year Est. Return
CC
Chanos & Company New York $318M AUM 4.62% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

International Biotechnology Trust's Q3 2018 Portfolio in Review

As of Q3 2018, International Biotechnology Trust held 57 positions worth $210M, down 19% from $260M the previous quarter. Its ten largest holdings account for 50% of the portfolio.

International Biotechnology Trust's Q3 2018 filing shows 3 new, 11 increased, 5 reduced and 6 closed positions. Its largest new stake was Zogenix, Inc.: 110,000 shares worth $4.18M. The largest sale was Neurocrine Biosciences, an estimated $14.5M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • International Biotechnology Trust's largest Q3 2018 buy was Zogenix, Inc.: 110,000 shares worth $4.18M.
  • International Biotechnology Trust added most to Aerie Pharmaceuticals in Q3 2018, an estimated $7.1M increase.
  • International Biotechnology Trust's biggest Q3 2018 reduction was Neurocrine Biosciences, cutting an estimated $14.5M.
  • International Biotechnology Trust fully exited Biogen in Q3 2018, selling an estimated $10.5M.
  • International Biotechnology Trust's ten largest holdings make up 50% of its $210M portfolio in Q3 2018.
  • International Biotechnology Trust opened 3 new positions and closed 6 in Q3 2018.
  • International Biotechnology Trust's portfolio value fell 19% quarter-over-quarter to $210M.

Based on International Biotechnology Trust's 13F filing for Q3 2018, filed 13 Nov 2018.